Clinical Trial Update: Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sitravatinib plus pembrolizumab in advanced treatment-naïve PD-L1-positive non-squamous non-small cell lung cancer was terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Sitravatinib (sitravatinib)

Snippet

Sponsor: Sarah Goldberg | Conditions: Carcinoma, Non-Small-Cell Lung, Lung Diseases | Phase 2 | Status: TERMINATED | Results posted: 2025-04-17